IL94459A - Pharmaceutical form and process for its preparation - Google Patents

Pharmaceutical form and process for its preparation

Info

Publication number
IL94459A
IL94459A IL9445990A IL9445990A IL94459A IL 94459 A IL94459 A IL 94459A IL 9445990 A IL9445990 A IL 9445990A IL 9445990 A IL9445990 A IL 9445990A IL 94459 A IL94459 A IL 94459A
Authority
IL
Israel
Prior art keywords
freeze
paste
dried
pharmaceutical form
unitary
Prior art date
Application number
IL9445990A
Other languages
English (en)
Hebrew (he)
Other versions
IL94459A0 (en
Original Assignee
Rhone Poulenc Sante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Sante filed Critical Rhone Poulenc Sante
Publication of IL94459A0 publication Critical patent/IL94459A0/xx
Publication of IL94459A publication Critical patent/IL94459A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Materials For Medical Uses (AREA)
  • Filtering Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL9445990A 1989-05-24 1990-05-21 Pharmaceutical form and process for its preparation IL94459A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8906781A FR2647343B1 (fr) 1989-05-24 1989-05-24 Nouvelle forme pharmaceutique poreuse et sa preparation

Publications (2)

Publication Number Publication Date
IL94459A0 IL94459A0 (en) 1991-03-10
IL94459A true IL94459A (en) 1995-01-24

Family

ID=9381955

Family Applications (2)

Application Number Title Priority Date Filing Date
IL94460A IL94460A0 (en) 1989-05-24 1990-05-21 Pharmaceutical compositions containing imipramine or derivatives thereof
IL9445990A IL94459A (en) 1989-05-24 1990-05-21 Pharmaceutical form and process for its preparation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL94460A IL94460A0 (en) 1989-05-24 1990-05-21 Pharmaceutical compositions containing imipramine or derivatives thereof

Country Status (24)

Country Link
US (1) US5244881A (de)
EP (2) EP0399902B1 (de)
JP (1) JP2948271B2 (de)
KR (1) KR0163423B1 (de)
AT (2) ATE98867T1 (de)
AU (2) AU631888B2 (de)
CA (2) CA2017360A1 (de)
DD (1) DD297915A5 (de)
DE (2) DE69000641T2 (de)
DK (2) DK0399903T3 (de)
ES (2) ES2054289T3 (de)
FI (1) FI103712B (de)
FR (1) FR2647343B1 (de)
GR (1) GR3006655T3 (de)
IE (2) IE64370B1 (de)
IL (2) IL94460A0 (de)
NO (1) NO180517C (de)
NZ (2) NZ233766A (de)
PL (1) PL285327A1 (de)
PT (2) PT94138B (de)
TW (1) TW257672B (de)
WO (1) WO1990014089A1 (de)
YU (1) YU100790A (de)
ZA (2) ZA903895B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE196426T1 (de) * 1991-06-21 2000-10-15 Takeda Chemical Industries Ltd Zyklodextrin-zusammensetzung enthaltend fumagillol-derivate
AU666509B2 (en) 1991-12-24 1996-02-15 Yamanouchi Pharmaceutical Co., Ltd. Intrabuccally disintegrating preparation and production thereof
GB9318880D0 (en) * 1993-09-11 1993-10-27 Smithkline Beecham Plc Pharmaceutical composition
JPH10500982A (ja) * 1994-05-27 1998-01-27 ファーマーク、ネダーランド、ベスローテン、フェンノートシャップ 医薬組成物
EP0973507B1 (de) * 1997-02-20 2009-01-21 Massachussets Institute of Technology Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
BE1011251A3 (fr) 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
TW527195B (en) 1997-10-09 2003-04-11 Ssp Co Ltd Fast-soluble solid pharmaceutical combinations
NZ506389A (en) * 1998-02-05 2003-07-25 Novartis Ag Pharmaceutical compositions containing epothilone which can be optionally lyophilised
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
US6287603B1 (en) * 1999-09-16 2001-09-11 Nestec S.A. Cyclodextrin flavor delivery systems
AU2003201161B2 (en) 2002-01-15 2008-02-28 Ucb Farchim S.A. Formulations
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
HUP0500134A3 (en) 2002-02-25 2009-12-28 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
DE10239531A1 (de) 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
DE10248314A1 (de) * 2002-10-16 2004-04-29 Dr. Suwelack Skin & Health Care Ag Verwendung von Formkörpern zur äußeren Anwendung
FR2876910B1 (fr) * 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
NZ561664A (en) 2005-02-24 2011-02-25 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
WO2008136900A1 (en) 2007-04-13 2008-11-13 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
JP2009091309A (ja) * 2007-10-10 2009-04-30 Japan Organo Co Ltd バコパモニエラエキスを含有する組成物およびその製造方法ならびに飲食品
CN101878040A (zh) 2007-10-31 2010-11-03 扩散药品有限公司 一类促进小分子扩散的新型治疗剂
CN102143737A (zh) * 2008-09-05 2011-08-03 麦克内尔-Ppc股份有限公司 制备西替利嗪片剂的方法
US10130689B2 (en) 2009-06-22 2018-11-20 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
CA2801292C (en) 2010-06-02 2019-01-22 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
US9018193B2 (en) * 2010-09-13 2015-04-28 Bev-Rx, Inc. Aqueous drug delivery system
RU2609198C1 (ru) * 2016-01-25 2017-01-30 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма имипрамина немедленного высвобождения и способ ее получения
JP7032320B2 (ja) 2016-03-24 2022-03-08 ディフュージョン・ファーマシューティカルズ・エルエルシー 癌を処置するための、化学療法及び放射線療法を伴う二極性トランスカロテノイドの使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5443570B2 (de) * 1972-10-27 1979-12-20
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
US4165382A (en) * 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
US4349472A (en) * 1979-04-27 1982-09-14 Schering Corporation (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
US4284555A (en) * 1979-04-27 1981-08-18 Schering Corporation 7-Chloro-8(substituted amino carbonyloxy)-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US4477378A (en) * 1980-02-05 1984-10-16 Schering Corp. Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
KR860700352A (ko) * 1984-11-27 1986-10-06 후지와라 도미오 2--(1-피페라지닐)-4-치환 페닐퀴놀린 유도체와 그 염의 제조방법
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition

Also Published As

Publication number Publication date
ZA903895B (en) 1991-03-27
NO902280D0 (no) 1990-05-23
PT94139A (pt) 1991-01-08
ES2054289T3 (es) 1994-08-01
IE901862L (en) 1990-11-24
AU631888B2 (en) 1992-12-10
PT94138A (pt) 1991-01-08
DE69005359D1 (de) 1994-02-03
CA2017360A1 (fr) 1990-11-24
IE63317B1 (en) 1995-04-05
IL94460A0 (en) 1991-03-10
EP0399903B1 (de) 1992-12-23
CA2017355A1 (fr) 1990-11-24
JP2948271B2 (ja) 1999-09-13
TW257672B (de) 1995-09-21
JPH0356412A (ja) 1991-03-12
AU623779B2 (en) 1992-05-21
KR0163423B1 (ko) 1998-12-01
NO902280L (no) 1990-11-26
ZA903978B (en) 1991-03-27
KR900017570A (ko) 1990-12-19
GR3006655T3 (de) 1993-06-30
DK0399902T3 (da) 1994-02-14
DE69000641D1 (de) 1993-02-04
PT94139B (pt) 1996-12-31
PT94138B (pt) 1996-12-31
FI902553A0 (fi) 1990-05-23
ATE98867T1 (de) 1994-01-15
NO180517C (no) 1997-05-07
EP0399902B1 (de) 1993-12-22
US5244881A (en) 1993-09-14
DK0399903T3 (da) 1993-02-08
FI103712B1 (fi) 1999-08-31
EP0399902A1 (de) 1990-11-28
FI103712B (fi) 1999-08-31
ES2062437T3 (es) 1994-12-16
IE64370B1 (en) 1995-07-26
FR2647343B1 (fr) 1994-05-06
DE69000641T2 (de) 1993-06-09
AU5743390A (en) 1990-12-18
DD297915A5 (de) 1992-01-30
AU5582890A (en) 1991-01-10
PL285327A1 (en) 1991-02-11
WO1990014089A1 (fr) 1990-11-29
YU100790A (en) 1992-05-28
NZ233766A (en) 1991-08-27
NZ233784A (en) 1993-04-28
NO180517B (no) 1997-01-27
DE69005359T2 (de) 1994-05-05
FR2647343A1 (fr) 1990-11-30
IL94459A0 (en) 1991-03-10
EP0399903A1 (de) 1990-11-28
IE901821L (en) 1990-11-24
ATE83663T1 (de) 1993-01-15

Similar Documents

Publication Publication Date Title
US5206025A (en) Porous pharmaceutical form and its preparation
IL94459A (en) Pharmaceutical form and process for its preparation
US4835187A (en) Spray dried ibuprofen
US5505959A (en) Pharmaceutical composition in gel form in a dispensing package
JP4336021B2 (ja) 口腔内崩壊型錠剤およびその製造法
KR100852015B1 (ko) 무젤라틴의 급속 분산성 제형
US4760094A (en) Spray dried acetaminophen
KR890002949B1 (ko) 경구용 약제 조성물의 제조방법
EP0873749B1 (de) Gelierte arzneimittel zur oralen verabreichung
US4835188A (en) Spray dried ibuprofen
KR101590115B1 (ko) 약학 조성물
US4835186A (en) Spray dried ibuprofen
JPH10510817A (ja) チュアブル製剤
EA000046B1 (ru) Оральная композиция, содержащая s(+)-ибупрофен, и способ ее получения
JP2002535269A (ja) 粘膜分配用組成物と方法
US4771077A (en) Spray dried acetaminophen
JP4309481B2 (ja) ゼリー状経口医薬組成物
JPH11199517A (ja) 口腔内速崩壊性錠剤
JP2511577B2 (ja) アルギン酸プロピレングリコ―ルエステルからなる徐放性製剤
JP2002308760A (ja) 圧縮成型用組成物及びその利用
JP4634589B2 (ja) 食品又は医薬品易服用化剤
JP2018500278A (ja) 外部粘膜に適用する剤形物品
JPH051243B2 (de)
JP2008133294A (ja) 口腔内崩壊型錠剤
JPH09216816A (ja) 高水溶性固形医薬用速溶錠

Legal Events

Date Code Title Description
KB Patent renewed
RH Patent void